Biocon Biologics' Vision for the Future: Expanding Access to Affordable Biologics

Biocon Biologics, a subsidiary of Biocon Ltd, has achieved a significant milestone with the U.S. FDA approval of Jobevne, a biosimilar to Bevacizumab (Avastin), for intravenous use. This approval marks the seventh biosimilar cleared by the FDA for Biocon Biologics and expands its oncology portfolio in the United States.

Key Highlights:

Jobevne Approval: Jobevne is a recombinant humanized monoclonal antibody used to treat various types of cancer, including metastatic colorectal cancer, non-squamous non-small cell lung cancer, recurrent glioblastoma, and metastatic renal cell carcinoma. It functions as a vascular endothelial growth factor (VEGF) inhibitor, preventing angiogenesis and restricting blood supply to tumors.

Market Impact: The approval of Jobevne positions Biocon Biologics strongly in the U.S. oncology market, where Bevacizumab sales reached approximately $2 billion in 2023. This biosimilar offers a more affordable alternative to Avastin, enhancing access to cancer treatments.

Portfolio Expansion: Jobevne joins Biocon Biologics' existing U.S. oncology portfolio, which includes OGIVRI (Trastuzumab-dkst) and FULPHILA (Pegfilgrastim-jmdb). The company also markets Bevacizumab under the name ABEVMY in Europe and Canada.

Global Presence: Biocon Biologics serves over five million patients annually and has a robust development pipeline of 20 biosimilar assets across multiple therapy areas. The company has achieved several industry firsts, including the first U.S. approval of a trastuzumab biosimilar and an interchangeable insulin biosimilar.

Source: PR Newswire, Business Standard, Express Pharma